UK vehicle production continues to face constraints, with figures from the Society of Motor Manufacturers and Traders (SMMT) ...

Nationwide Vehicle Contracts warns of fundamental industry shifts, with battery tech and servicing models set for overhaul as ...

UK van sales dropped 12.1% in H1 2025, with tax changes and weak economic confidence stalling fleet renewal and slowing the ...

Amid a tough economic environment and weak business confidence to invest in fleet renewal, the UK’s new LCV market continues ...

Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

The new car market recorded its second consecutive month of growth in June, with registrations rising 6.7% year-on-year ...

As a result, Britain say the strongest June for new car sales since 2019, with 191,316 cars registered, according to the ...

Fintel reports that on July 1, 2025, UBS initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a Buy recommendation.

UK EV market expands, but rising costs, Chinese competition, and lagging infrastructure are slowing the industry.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Sales remained below pre-COVID levels, but it was the best June since 2019, the Society of Motor Manufacturers and Traders ...

UK carmakers are on course to meet this year’s electric vehicle (EV) sales targets, despite having successfully lobbied the ...